P53 activation is closely associated with increased hepatic steatosis and fibrosis.[19, 47] In MASH, P53 activation promotes adipocyte differentiation and hepatic steatosis.[47] Thus, modulating P53 activity is critical for mitigating MASH‐related pathological changes. Here, TP53 is linked to fatty liver disease.